Experimental hepatitis C drug slows Zika virus infection in mice
17 May 2016 | By Katie Sadler
Virologists have discovered that an antiviral drug against hepatitis C has helped slow down the development of Zika virus in Mice.
List view / Grid view
17 May 2016 | By Katie Sadler
Virologists have discovered that an antiviral drug against hepatitis C has helped slow down the development of Zika virus in Mice.
14 December 2015 | By Victoria White
Their research identified eight complete strains of human pegivirus 2, which makes it the first study to reveal the entire genetic makeup of this new virus...
4 June 2015 | By Victoria White
VBI Vaccines has delivered a presentation that supports the potential use of its eVLP platform in the development of a novel Hepatitis C vaccine candidate...
22 May 2015 | By Victoria White
Achillion and Janssen have entered into a worldwide license and collaboration arrangement to develop and commercialise one or more of Achillion's HCV assets...
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
6 May 2014 | By Red Door Communications
New evidence published to coincide with the International Liver Meeting showing the potential for elimination of hepatitis C across 15 countries by 2030...
10 April 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir...
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...